Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

UWC reported for 6 months of 2024 by RAS

7/29/24 UWGN

APRI IPO went over the top

7/29/24 APRI

Zvezda reported for 6 months of 2024 by RAS

7/29/24 ZVEZ

Nornickel reports for 6 months of 2024 by RAS

7/29/24 GMKN

TGC-2 reported for 6 months of 2024 by RAS

7/29/24 TGKB

Ryazanenergosbyt reported for 6 months of 2024 by RAS

7/29/24 RZSB

INARCTICA reported for 6 months of 2024 by RAS

7/29/24 AQUA

Himprom reported for 6 months of 2024 by RAS

7/29/24 HIMCP

Nornickel's production performance continued to decline

7/29/24 GMKN

Lenta reported an increase in performance

7/29/24 LENT